Ipsen Pharma Company Basic Information, and Sales Area
|Company Name||Ipsen Pharma|
|Market Position/ History||Ispen Pharma is based in France offers pipeline products across 115 countries with its presence in more than 30 countries. The company has R&D and manufacturing facilities located in China, France, Ireland, the United Kingdom, and the United States.|
|Contact Information||65 quai Georges Gorse
Boulogne Billancourt, France
Business Segment/ Overview:
Ipsen Pharma is biopharmaceutical-based company which has diverse range of products such as carbometyx, cometriq, decapeptyl, dysport, increlex, nutropinAq. onivyde 9/irinotecan liposome injection, somatuline and xermelo. These products are offered under several therapeutic areas such as oncology, neuroscience, consumer healthcare, rare disease. The company invested $476.22 million in R&D, which is 14.9 % of sales.
The company has included pipeline products in their portfolio, which involves:
• Carbometyx + atezolizumab- Phase 1 trial for solid tumors
• IPN59011 longer acting neurotoxin Ax
• IPN10200Longer-acting neurotoxin Ax / Tx
• mesdopetam PD-LID for phase 2 trial
• Onivyde 2L SCLC for phase 3 trials
• Onivyde 1L PDAC2 for phase 3 trials
• Elafibranor2 PBC for phase 3 trials
The company has invested in R&D activities in oncology, rare disease and neuroscience. Further, the company specializes in the areas of hepatocellular carcinoma, neuroendocrine tumors. prostate cancer, pancreatic cancer.
Onivyde, which received commercialization rights outside the U.S. and Taiwan. Onivyde is USFDA approved form of liposome used for treatment of patients with metastatic adenocarcinoma of pancreas a after disease progression following gemcitabine-based therapy. Limitation of Use: Onivyde is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas. It is also known as irinotecan liposome injection. (Onivyde) in combination with 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) as a potential first-line treatment for metastatic pancreatic ductal adenocarcinoma cancer patients.
Ispen Pharma introduced Phase 1/2 clinical data of Liposomal Irinotecan or Onivyde
Ispen Pharma launched Phase 1/2 clinical data of Liposomal Irinotecan or Onivyde liposomal as an investigational first line drug for metastatic pancreatic cancer at the ESMO world congress on Gastrointestinal cancer.
Ipsen Pharma received FDA Fast Track for investigational liposome injection, Onivyde
Ipsen Pharma has received FDA Fast Track for investigational liposome injection, Onivyde, as a second line monotherapy treatment for small cell lung cancer.
Smruti Ransingh, holding a Bachelor's degree in Electronics and Telecommunication Engineering, is a seasoned market researcher in the Electronics & Electrical industry. Over the years, she has collaborated with key players in the field, aiding them in identifying market prospects and offering effective strategic solutions. Her proficiency lies in integrating qualitative and quantitative research techniques to conduct Market Assessments that steer business choices.